Applied Therapeutics Inc.

16.82+1.46+9.51%Vol 126.64K1Y Perf -18.79%
Sep 23rd, 2021 12:39 DELAYED
BID16.77 ASK16.83
Open15.45 Previous Close15.36
Pre-Market- After-Market-
 - -%  - -
Target Price
60.00 
Analyst Rating
Strong Buy 1.00
Potential %
257.36 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-79/-88/-92 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-76/-80/-80 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-71/-76/-78 
Income Ranking
 —    -
Price Range Ratio 52W %
22.55 
Earnings Rating
Strong Buy
Market Cap440.31M 
Earnings Date
11th Nov 2021
Alpha0.03 Standard Deviation0.28
Beta1.13 

Today's Price Range

15.4516.89

52W Range

13.0429.80

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
6.96%
1 Month
-13.80%
3 Months
-38.66%
6 Months
-21.67%
1 Year
-18.79%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APLT16.821.46009.51
AAPL146.680.83000.57
GOOG2 839.7821.01000.75
MSFT299.731.15000.39
XOM57.101.89003.42
WFC48.000.92001.95
JNJ165.601.67001.02
FB346.273.06000.89
GE103.575.03005.10
JPM161.185.27003.38
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.99-0.990.00
Q01 2021-1.06-1.005.66
Q04 2020-1.31-1.0619.08
Q03 2020-1.04-1.33-27.88
Q02 2020-0.72-1.27-76.39
Q01 2020-0.75-0.5921.33
Q04 2019-0.63-1.57-149.21
Q03 2019-0.37-0.63-70.27
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.9910.00Positive
9/2021 QR-1.100.00-
12/2021 FY-4.20-320.00Negative
12/2022 FY-3.5818.82Positive
Next Report Date11th Nov 2021
Estimated EPS Next Report-0.99
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume126.64K
Shares Outstanding26.18M
Shares Float17.72M
Trades Count468
Dollar Volume2.43M
Avg. Volume105.58K
Avg. Weekly Volume137.25K
Avg. Monthly Volume115.98K
Avg. Quarterly Volume93.68K

Applied Therapeutics Inc. (NASDAQ: APLT) stock closed at 15.36 per share at the end of the most recent trading day (a 0.33% change compared to the prior day closing price) with a volume of 167.26K shares and market capitalization of 440.31M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. Applied Therapeutics Inc. CEO is Shoshana Shendelman.

The one-year performance of Applied Therapeutics Inc. stock is -18.79%, while year-to-date (YTD) performance is -30.21%. APLT stock has a five-year performance of %. Its 52-week range is between 13.04 and 29.8, which gives APLT stock a 52-week price range ratio of 22.55%

Applied Therapeutics Inc. currently has a PE ratio of -3.30, a price-to-book (PB) ratio of 3.32, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.99%, a ROC of -82.04% and a ROE of -82.89%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Applied Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.99 for the next earnings report. Applied Therapeutics Inc.’s next earnings report date is 11th Nov 2021.

The consensus rating of Wall Street analysts for Applied Therapeutics Inc. is Strong Buy (1), with a target price of $60, which is +257.36% compared to the current price. The earnings rating for Applied Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Applied Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Applied Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.81, ATR14 : 1.17, CCI20 : -4.53, Chaikin Money Flow : 0.11, MACD : -0.65, Money Flow Index : 38.33, ROC : -3.52, RSI : 48.03, STOCH (14,3) : 68.04, STOCH RSI : 1.00, UO : 52.08, Williams %R : -31.96), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Applied Therapeutics Inc. in the last 12-months were: Adam Hansard (Sold 2 894 shares of value $53 105 ), Charles Silberstein (Sold 5 047 shares of value $108 107 ), Les Funtleyder (Sold 30 000 shares of value $141 000 ), Les Funtleyder (Sold 30 000 shares of value $602 113 ), Riccardo Perfetti (Option Excercise at a value of $135 942), Riccardo Perfetti (Sold 95 794 shares of value $1 874 047 ), Shoshana Shendelman (Buy at a value of $145 038), Stacy J. Kanter (Buy at a value of $148 590)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart.

CEO: Shoshana Shendelman

Telephone: +1 212 220-9226

Address: 545 Fifth Avenue, New York 10173, NY, US

Number of employees: 22

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

59%41%

Bearish Bullish

60%40%

News

Stocktwits